Carlsmed vs LENSAR
LENSAR reported revenue of $58 million in fiscal 2025, 1.2 times Carlsmed's $50 million in fiscal 2025. Carlsmed's revenue grew 85.9% in its latest year, and LENSAR's grew 9.2%. Carlsmed had an operating margin of -60.5%, against -42.1% at LENSAR. Free cash flow was −$30 million at Carlsmed and −$15 million at LENSAR.
Side by side
| Carlsmed | LENSAR | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $50M | $58M |
| Revenue growth | 85.9% | 9.2% |
| Revenue growth a year, last 5 years | — | 17.2% |
| Gross margin | 75.3% | 46.4% |
| Operating margin | −60.5% | −42.1% |
| Net margin | −58.7% | −58.7% |
| Free cash flow | −$30M | −$15M |
| Free cash flow margin | −58.6% | −25.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 249.7% | 3.8% |
| Last close | $17.22 | $4.64 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $2.6 million | sold $169,989 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CarlsmedLENSAR
Operating margin
Percent of revenue
CarlsmedLENSAR
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CarlsmedLENSAR